Your account is not claimed yet. You can sign up with ORCID to claim your account.

Michael Pascal Hengartner (Michael P Hengartner, M P Hengartner)

Loop profile Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2015-2023
Publications (10 Years): 20

Top Venues

BMJ evidence-based medicine

Therapeutic advances in psychopharmacology

Personality and mental health

Molecular psychiatry

Zurich University of Applied Sciences (ZHAW)

University of Zurich (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Zurich University of Applied Sciences (ZHAW) May 1o 2014

Switzerland

Research Fellow :: Department of Applied Psychology

Education History

University of Zurich

Switzerland

PHD :: Department of Psychiatry, Psychotherapy and Psychosomatics

Publications

Melanie Alexandra Amrein, Michael Pascal Hengartner, Markus Näpflin, Renato Farcher, Carola A Huber
Prevalence, trends, and individual patterns of long-term antidepressant medication use in the adult Swiss general population. European journal of clinical pharmacology (2023)
Joanna Moncrieff, Ruth E Cooper, Tom Stockmann, Simone Amendola, Michael Pascal Hengartner, Martin Plöderl, Mark A Horowitz
The serotonin hypothesis of depression: both long discarded and still supported? Molecular psychiatry (2023)
Martin Plöderl, Joakim Westerlund, Sebastian Hökby, Gergö Hadlaczky, Michael Pascal Hengartner
Increased suicide risk among younger women in winter during full moon in northern Europe. An artifact or a novel finding? Molecular psychiatry (2022)
Wulf Rössler, Wolfram Kawohl, Carlos Nordt, Helene Haker, Nicolas Rüsch, Michael Pascal Hengartner
'Placement budgets' for supported employment: impact on employment rates in a multicentre randomised controlled trial. The British journal of psychiatry : the journal of mental science 216 (6) (2021)
Michael Pascal Hengartner, Martin Plöderl
Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ evidence-based medicine (2021)
Michael Pascal Hengartner, Simone Amendola, Jakob A Kaminski, Simone Kindler, Tom Bschor, Martin Plöderl
Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies. Journal of epidemiology and community health (2021)
Michael Pascal Hengartner, Martin Plöderl
Prophylactic effects or withdrawal reactions? An analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA. Therapeutic advances in psychopharmacology 11 (2021)
Constantin Volkmann, M Plöderl, Michael Pascal Hengartner
Comment on Osler et al: Misinterpretation of pre-post differences invalidates the authors' conclusions. Acta psychiatrica Scandinavica 140 (6) (2020)
Michael Pascal Hengartner, Lukas Schulthess, Anders Sorensen, Adele Framer
Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum. Therapeutic advances in psychopharmacology 10 (2020)
Michael Pascal Hengartner, Janus C Jakobsen, Anders Sørensen, Martin Plöderl
Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials. PloS one 15 (2) (2020)
Michael Pascal Hengartner
How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding. Therapeutic advances in psychopharmacology 10 (2020)
Michael Pascal Hengartner
Is there a genuine placebo effect in acute depression treatments? A reassessment of regression to the mean and spontaneous remission. BMJ evidence-based medicine 25 (2) (2019)
Michael Pascal Hengartner, James Davies, John Read
Antidepressant withdrawal - the tide is finally turning. Epidemiology and psychiatric sciences 29 (2019)
Martin Plöderl, Michael Pascal Hengartner
What are the chances for personalised treatment with antidepressants? Detection of patient-by-treatment interaction with a variance ratio meta-analysis. BMJ open 9 (12) (2019)
Michael Pascal Hengartner
Scientific debate instead of beef; challenging misleading arguments about the efficacy of antidepressants. Acta neuropsychiatrica 31 (4) (2019)
Michael Pascal Hengartner, Martin Plöderl
Starting two antidepressants to prevent suicide: A potentially dangerous recommendation? The Australian and New Zealand journal of psychiatry 53 (1) (2018)
Michael Pascal Hengartner
What is the threshold for a clinical minimally important drug effect? BMJ evidence-based medicine (2018)
Michael Pascal Hengartner, Markus Graf, Marc Schreiber
Traits across the personality hierarchy differentially relate to positive and negative affect: Evidence for the predictive validity of empirically derived meta-traits. Personality and mental health 11 (2) (2017)
Michael Pascal Hengartner, Dimitri van der Linden, Laura Bohleber, Agnes von Wyl
Big Five Personality Traits and the General Factor of Personality as Moderators of Stress and Coping Reactions Following an Emergency Alarm on a Swiss University Campus. Stress and health : journal of the International Society for the Investigation of Stress 33 (1) (2016)
Michael Pascal Hengartner, Agnes von Wyl, Thachell Tanis, Winter Halmi, Igor Galynker, Lisa J Cohen
Severity of personality disorders and domains of general personality dysfunction related to attachment. Personality and mental health 9 (3) (2015)

Michael Pascal Hengartner.css-eqlu8i{font-size:small;padding-left:4px;} (Michael P Hengartner, M P Hengartner)

Publication Activity (10 Years)

Top Topics

Top Venues

Michael Pascal Hengartner (Michael P Hengartner, M P Hengartner)